ArticleEClinicalMedicine2023

Parsaclisib, a PI3Kδ inhibitor, in relapsed and refractory mantle cell lymphoma (CITADEL-205): a phase 2 study.

Pier Luigi Zinzani et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.